ArticleStem cell research & therapy2025
A core-shell multifunctional microneedle patch accelerates infected diabetic wound healing.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A ROS-responsive core-shell microneedle platform integrating sonodynamic gas antibacterial therapy and modulating immunity for diabetic wound healing.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Diabetic wounds exhibit impaired angiogenesis, drug-resistant bacterial infections, and oxidative damage to the microenvironment, presenting ongoing clinical challenges. In this research, we designed a core-shell structured multifunctional microneedle (MN) array patch (CS-SDFP/HA-Ag@MOF-PAL) to expedite the healing of infected diabetic wounds. The core consists of 10,000 MV hyaluronic acid (HA) and sucrose, integrated with Ag@MOF loaded with Palmatine (Ag@MOF-PAL). The shell, composed of chitosan (CS), encapsulates SDFP (CS-SDFP). Upon application to an infected diabetic wound, the shell swells, releasing the HA core, which dissolves to release Ag@MOF-PAL. The Ag@MOF targets and eradicates bacteria and eliminates biofilms of bacteria in the wound area, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, while PAL mitigates chronic inflammation in wound macrophages via the NF-κB and MAPK signaling pathways. As the wound microenvironment normalizes, the SDFP released from the swollen CS recruits adipose-derived stem cells (ADSCs) and promotes angiogenesis to facilitate wound repair. Our experiments demonstrate that CS-SDFP/HA-Ag@MOF-PAL accelerates wound healing in a diabetic rat model with Pseudomonas aeruginosa-infected wounds. The property of this core-shell structured multifunctional MN patch presents considerable potential for the development of therapeutic strategies aimed at the healing of infected diabetic wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.